Business Context and Reporting Period
Company: Safety Shot, Inc. (Note: Input metadata referenced "BONK, INC." but the filing text identifies the registrant as Safety Shot, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: August 30, 2024 (Event Date); Signed September 5, 2024
Reporting Period: Specific event reporting regarding a capital raise transaction.
Key Financial Metrics and Transaction Details
This filing reports a private placement transaction rather than standard periodic financial results. Key metrics include:
- Shares Issued: 3,370,787 shares of Common Stock.
- Share Price: $0.89 per share (based on closing price August 29, 2024).
- Warrants Issued: 3,370,787 warrants (1:1 ratio with shares).
- Warrant Terms: Exercise price of $0.89; 5-year term; issued at $0.125 per warrant.
- Net Proceeds: Approximately $3,421,348 (no commissions paid).
- Investor Profile: One accredited investor. The Company's President, Jordan Schur, owns 15% of the Investor, and other shareholders are members of his immediate family.
Material Changes
The filing discloses the entry into a Material Definitive Agreement (Securities Purchase Agreement) and the unregistered sale of equity securities. There is no prior comparable period data provided in this specific 8-K filing to calculate percentage changes in revenue or profit.
Guidance, Outlook, and Risks
- Regulatory Status: Securities issued under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D (unregistered).
- Related Party Transaction: The transaction involves a related party (President Jordan Schur), which may present conflicts of interest or require specific shareholder disclosures not detailed in this summary.
- Emerging Growth Company: The registrant is an emerging growth company.
- Outlook: The filing does not provide specific forward-looking guidance on revenue or earnings, only the immediate capital infusion.
Investor Verification Checklist
- Verify the exact ownership structure of the "Investor" to confirm the extent of Jordan Schur's influence beyond the stated 15%.
- Confirm the dilution impact of the 3,370,787 new shares and the potential future dilution from the 3,370,787 warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants or liquidation preferences.
- Check the press release dated September 4, 2024 (Exhibit 99.1) for additional context on the use of proceeds.
- Confirm the company's current cash position post-transaction to assess liquidity runway.